Revolution Medicines

What Revolution Medicines does

Revolution Medicines, Inc. (NASDAQ: RVMD) is a late-stage clinical oncology biotechnology company founded in 2014 and headquartered in Redwood City, California, developing a deep pipeline of RAS(ON) inhibitors for patients with RAS-addicted cancers—which the company estimates represent approximately 30% of all new human cancer diagnoses. Its core technology is a proprietary tri-complex inhibitor platform that uses chemical remodeling of chaperone proteins (notably cyclophilin A) to create novel druggable interfaces on RAS(ON) proteins, which were historically considered undruggable due to their smooth surfaces lacking classical small-molecule binding sites. The pipeline is anchored by daraxonrasib (RMC-6236), an oral RAS(ON) multi-selective inhibitor with positive Phase 3 RASolute 302 data in metastatic pancreatic ductal adenocarcinoma and four global Phase 3 registrational trials ongoing, alongside zoldonrasib (RMC-9805, G12D-selective), elironrasib (RMC-6291, G12C-selective), RMC-5127 (G12V-selective), and earlier-stage candidates including the novel catalytic inhibitor RM-055.

The company is pre-revenue and currently generates no commercial product sales; revenue is expected post-FDA approval through specialty pharmacy distribution of daraxonrasib in the US and analogous channels in Europe and Asia Pacific. Its go-to-market model is enterprise oncology field sales combined with Medical Science Liaison engagement, market access teams, and country-level general managers being established in the US, UK, Switzerland, Germany, France, Italy, Spain, the Netherlands, Austria, Belgium, Luxembourg, the Nordics, Japan, and broader Asia Pacific. Patient access pre-approval is being delivered through clinical trials and an FDA-authorized Expanded Access Program distributed by Bionical Emas. The firm monetizes through future pharmaceutical product sales (analyst projections indicate approximately $1.0 billion in revenue by 2029 and $5–7 billion+ peak annual sales potential for daraxonrasib in pancreatic cancer alone), supplemented by a $2.1 billion equity/convertible debt raise in April 2026 and a $2 billion flexible funding agreement with Royalty Pharma signed in June 2025.

Revolution Medicines' primary customer segments are oncology patients with RAS-mutant tumors—predominantly pancreatic, non-small cell lung, and colorectal cancers—reached through medical oncologists, gastroenterological oncologists, and specialized cancer treatment centers. Secondary counterparties include biopharmaceutical partners engaged in combination-therapy development (e.g., the Tango Therapeutics vopimetostat + daraxonrasib collaboration) and academic collaborators such as UCSF and the NCI RAS Initiative. The company holds FDA Breakthrough Therapy, Orphan Drug, and Fast Track designations for daraxonrasib in pancreatic cancer, has secured issued US patents underpinning its tri-complex platform, and has a management team and board drawn substantially from Genentech/Roche, Moderna, Merck, BMS, Mirati, and AstraZeneca.

Name

Revolution Medicines

Legal name

Revolution Medicines, Inc.

Website

https://revmed.com

Company type

Public

Founded year

2014

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Revolution Medicines is a late-stage clinical oncology biotech developing RAS(ON) inhibitors using its proprietary tri-complex platform to target RAS-addicted cancers—primarily pancreatic, lung, and colorectal—serving patients through oncologists and specialty pharmacies with daraxonrasib and a multi-candidate pipeline.

Ownership category

akta.pro rank

Product category

Oncology Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Oncology & Hematology Pharmaceuticals (HLAIAAAC)

akta.pro secondary industries

Gastroenterology Specialty Pharmaceuticals (HLAIACAE), Genitourinary Oncology (HLAKAFAM)

Keywords

• Oncology drug development
• RAS inhibitor therapeutics
• Targeted cancer therapy
• Precision oncology biotech
• Clinical-stage biotechnology

Headquarters

HQ city

Redwood City

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Pre-revenue clinical stage company. Revenue expected from commercial sales of daraxonrasib and other RAS(ON) inhibitors upon FDA approval. Analysts project $5-7 billion+ peak annual sales potential for daraxonrasib in pancreatic cancer alone.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Revolution Medicines is a clinical-stage oncology company developing a deep pipeline of RAS(ON) inhibitor drug candidates using its proprietary tri-complex inhibitor platform. Its lead candidate daraxonrasib (RMC-6236) plus mutation-selective candidates (zoldonrasib/RMC-9805 for G12D, elironrasib/RMC-6291 for G12C, RMC-5127 for G12V) and preclinical assets target RAS-driven cancers including pancreatic, lung, and colorectal malignancies.

Product overview

Revolution Medicines is a late-stage clinical oncology company developing a deep pipeline of RAS(ON) inhibitors using its proprietary tri-complex inhibitor platform. The company's first wave of investigational RAS(ON) inhibitors includes daraxonrasib (RMC-6236), a multi-selective inhibitor, elironrasib (RMC-6291), a G12C-selective inhibitor, and zoldonrasib (RMC-9805), a G12D-selective inhibitor, all currently in clinical development. Additional pipeline candidates include RMC-5127 (G12V), RMC-0708 (Q61H), RMC-8839 (G13C), and the preclinical RM-055 (catalytic inhibitor). The platform enables unprecedented access to the active form of oncogenic RAS by inducing chaperone proteins to form tri-complexes that block oncogenic signaling.

Differentiator

Problem solved

Functional benefit

Products and services

• Daraxonrasib (RMC-6236) Investigational oral RAS(ON) multi-selective non-covalent inhibitor designed to treat patients with cancers driven by a wide range of common RAS mutations. Currently in Phase 3 trials for metastatic pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC). For oncologists and cancer treatment centers treating RAS-driven solid tumors.
• Zoldonrasib (RMC-9805) Investigational oral RAS(ON) G12D-selective covalent inhibitor targeting RAS-G12D, the most common driver of RAS-addicted cancers. Currently in Phase 1/2 trials for metastatic PDAC and NSCLC, with Phase 3 trials planned. For oncologists treating G12D-mutated solid tumors.
• Elironrasib (RMC-6291) Investigational oral RAS(ON) G12C-selective covalent inhibitor designed to treat patients with cancers driven by KRAS-G12C mutations. Currently in early clinical development for solid tumors. For oncologists treating KRAS-G12C-mutated cancers.
• RMC-5127 Investigational oral RAS(ON) G12V-selective inhibitor targeting RAS-G12V, the second most common driver of RAS-addicted human cancers. Currently in early clinical development. For oncologists treating G12V-mutated solid tumors.
• RM-055 Novel mutant-targeted catalytic RAS(ON) inhibitor that works by accelerating hydrolysis of mutant RAS-GTP to RAS-GDP, converting oncogenic RAS from active ON state to inactive OFF state. Demonstrated antitumor activity in models resistant to prior RAS inhibitors. For oncology research and future clinical development.
• Tri-Complex Inhibitor Platform Chemical biology platform enabling chemical remodeling of chaperone proteins to inhibit frontier oncology targets through tri-complex formation. Creates molecules that bind to cyclophilin A to form novel interfaces with high affinity for RAS(ON) proteins. Internal drug discovery platform underlying all Revolution Medicines pipeline candidates.

Quantifiable outcome

• 60% reduction in risk of death (HR 0.40) vs chemotherapy in previously treated metastatic pancreatic cancer
• +4 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Five partnerships are on record, tiered major, minor and core.

• Tango TherapeuticsmajorStrategic or Co-development Partner · 1 June 2026Clinical collaboration for combination therapy using Tango Therapeutics' vopimetostat (PRMT5 inhibitor) with Revolution Medicines' daraxonrasib in MTAP-deleted pancreatic cancer. Phase 1/2 data showed 92% objective response rate supporting advancement to Phase 3.
• Bionical EmasminorChannel Partner/ Reseller/ Distributor · 1 April 2026Bionical Emas serves as the distributor for Revolution Medicines' Expanded Access Program for daraxonrasib in the United States, handling distribution logistics for the FDA-authorized early access program.
• EQRxcoreStrategic or Co-development Partner · 1 November 2023Revolution Medicines completed acquisition of EQRx in November 2023, adding approximately $1.1 billion in net cash and issuing about 55 million shares. The acquisition supports clinical development of targeted cancer therapies and brought Sandra Horning onto Revolution Medicines' board of directors. EQRx was co-founded by Alexis Borisy and aimed to develop affordable medicines.
• Columbia UniversityminorStrategic or Co-development PartnerResearch support from Columbia University contributed to development of daraxonrasib, with Columbia researchers collaborating on RAS(ON) inhibitor research supporting the clinical program.
• UCSF and NCI RAS InitiativeminorStrategic or Co-development PartnerRevolution Medicines builds on foundational KRAS research from UCSF and the National Cancer Institute's RAS Initiative, which provided scientific basis for targeting RAS in cancer.

Scale indicators11 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Mirati Therapeutics: Developed Krazati (adagrasib), a KRAS-G12C inhibitor directly competing with Revolution Medicines' elironrasib in the same target space. Acquired by Bristol Myers Squibb for $4.8B in 2024, Mirati validated the commercial opportunity for RAS-targeted oncology drugs and serves as the most direct comparable.
• BridgeBio Pharma: Late-stage clinical oncology and rare disease biotech with similar profile to Revolution Medicines: multi-asset pipeline, recent pivotal data readouts, and pre-commercial/early commercial stage. Comparable in capital intensity, pipeline breadth, and target market dynamics.
• Erasca: Direct RAS-MAPK pathway competitor developing ERAS-0015 and other RAS-targeted therapies, which triggered Revolution Medicines' April 2026 patent infringement letter. Operates in the same precision oncology space with overlapping clinical programs targeting RAS-driven cancers.
• Relay Therapeutics: Precision oncology company using motion-based drug design to target drivers of cancer, including RAS pathway and other solid tumor targets. Comparable in clinical-stage precision oncology focus, with board member Alexis Borisy also serving on Relay's board.

Broad incumbents

• Amgen: Markets Lumakras (sotorasib), the first FDA-approved KRAS-G12C inhibitor, competing head-to-head with elironrasib in NSCLC and other G12C-mutant tumors. As a global biopharma incumbent with established oncology commercial infrastructure, Amgen represents both a direct competitive threat and a benchmark for large-pharma RAS strategy.
• Bristol Myers Squibb: Global oncology leader that acquired Mirati Therapeutics (including Krazati) for $4.8B in 2024, making BMS the principal large-pharma competitor in the KRAS-G12C space. Represents both a competitive threat and a potential acquirer given BMS's track record of M&A in precision oncology.
• AstraZeneca: Major oncology incumbent with a competing RAS pipeline and established global commercial infrastructure in PDAC, NSCLC, and colorectal cancer. Comparable as a large-pharma benchmark for oncology commercial execution and potential strategic acquirer of complementary RAS assets.

Emerging players

• Tango Therapeutics: Clinical-stage synthetic lethality oncology company whose vopimetostat (PRMT5 inhibitor) is being combined with daraxonrasib in MTAP-deleted pancreatic cancer (92% ORR). Direct collaboration partner and overlapping target patient population in precision oncology.
• Black Diamond Therapeutics: Clinical-stage precision oncology biotech developing allosteric inhibitors of oncogenic proteins, including RAS-family targets. Comparable in mechanism-driven precision oncology approach and target patient population.
• Foghorn Therapeutics: Clinical-stage biotech targeting chromatin regulatory system in cancer, with overlap in precision oncology drug development approach and similar pre-commercial/early clinical stage profile to Revolution Medicines.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles23 records

Subsidiaries1 record

Funding overview

Funding rounds12 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Revolution Medicines